{"id":"W2287073069","doi":"10.1200/jco.2015.33.7_suppl.403","title":"Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sunitinib; Sorafenib; Interim analysis; Discontinuation; Internal medicine; Renal cell carcinoma; Adverse effect; Rash; Clinical endpoint; Hazard ratio; Placebo; Urology; Oncology; Surgery; Randomized controlled trial; Hepatocellular carcinoma; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002379232,0.000896569,0.001306639,0.0004068891,0.0003015869,0.0006427321,0.0006960217,0.0008431728,0.005189733],"category_scores_gemma":[0.001377713,0.0003444793,0.00107542,0.0004057341,0.0006801931,0.0005573643,0.0004121487,0.001733111,0.0007062612],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006396192,"about_ca_system_score_gemma":0.001213453,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007912261,"about_ca_topic_score_gemma":0.003897269,"domain_scores_codex":[0.9995068,0.0002910435,0.00002252783,0.00005244785,0.00005584567,0.00007121346],"domain_scores_gemma":[0.9994087,0.000129215,0.0001227461,0.00004754373,0.00003511816,0.0002566513],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9111466,0.008548029,0.003708235,0.0009880908,0.00084098,0.0001190596,0.0001192305,0.001870198,0.006483454,0.0004964549,0.006123026,0.05955659],"study_design_scores_gemma":[0.8248616,0.1547582,0.01172466,0.00007430741,0.0007559439,0.000294301,0.00003293487,0.00125463,0.001796551,0.0004092578,0.004015469,0.00002206887],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9818257,0.006118642,0.001036137,0.0007590325,0.0001570773,0.001798583,0.003230977,0.0002562057,0.004817605],"genre_scores_gemma":[0.9838532,0.002293731,0.002037116,0.0008962421,0.0002332015,0.002223367,0.004623475,0.00004096037,0.003798728],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005189733,"threshold_uncertainty_score":0.0173614,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3816231950379432,"score_gpt":0.5198697579504836,"score_spread":0.1382465629125404,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}